Roivant Sciences ROIV Income Statement
| Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| $638K-7.7% | $691K-25.0% | $921K-16.1% | $1.1M-22.9% | $1.43M-51.2% | ||
| $41.18M-4.8% | $43.27M-4.6% | $45.34M-6.2% | $48.32M-11.5% | $54.62M-11.7% | ||
| $12.57M+50.7% | $8.34M+247% | -$5.69M+49.2% | -$11.21M-294% | -$2.84M-1.0% | ||
| —— | $21.59M-83.2% | $128.5M+772% | -$19.13M-248% | $12.9M+161% | ||
| —— | -$265.89M-134% | -$113.52M+49.2% | -$223.36M-8.2% | -$206.48M-222% | ||
| $320K-54.3% | $700K+531% | $111K-27.9% | $154K-24.9% | $205K-20.8% | ||
| $1.32M+206% | $430K-64.3% | $1.21M+48.0% | $815K— | —— | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $16.16M+505% | -$3.99M-233% | $3M+126% | -$11.75M-7,018% | -$165K— | ||
| $63.23M— | —— | —— | -$25M— | —— | ||
| -$275K+65.0% | -$786K+7.1% | -$846K-77.0% | -$478K-98.3% | -$241K+88.0% | ||
| -$18.45M-775% | $2.73M-37.7% | $4.39M+3,530% | -$128K— | —— | ||
| —— | -$8.3M-359% | $3.21M+4,414% | $71K— | —— | ||
| $192.56M0.0% | $192.56M0.0% | $192.56M0.0% | $192.56M— | $0— | ||
| —— | $328.19M— | —— | -$187.77M-6.0% | -$177.15M+35.1% | ||
| —— | —— | —— | -$1.09B— | —— | ||
| -$163.82M+16.6% | -$196.48M-5.8% | -$185.66M+9.2% | -$204.38M-18.4% | -$172.57M+16.7% | ||
| $1.86M-26.2% | $2.53M+30.1% | $1.94M-0.1% | $1.94M-1.5% | $1.97M+15.3% | ||
| —— | —— | -$5.98M+46.0% | -$11.08M-162% | -$4.23M+64.5% | ||
| —— | —— | —— | $208.29M-29.5% | $295.45M+21.4% | ||
| $1.26M— | —— | $7.85M+94.5% | $4.04M+398% | $811K-55.6% | ||
| $51.19M-56.9% | $118.81M+74.0% | $68.29M+127% | $30.06M+139% | $12.59M-55.2% | ||
| $77.17M-26.5% | $105M+28.3% | $81.82M-0.4% | $82.18M-1.6% | $83.49M-0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Roivant Sciences's revenue?
- Roivant Sciences (ROIV) generated $8.3M in revenue over the trailing twelve months, down 71.6% year over year.
- Where does Roivant Sciences's income statement data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
